Sessa Capital (Master), L.P.

CIK: 0001618360

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (25.0%)

Derivative conversions

Awards (A)3 (75.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SABS

SAB Biotherapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

SABS
SAB Biotherapeutics, Inc.
Sep 29, 2025
Exercise(M)
Direct
1.7M shares at avg. $1.75$3.0M
SABS
SAB Biotherapeutics, Inc.
Jul 22, 2025
Award(A)
Series B Convertible Preferred Stock
Direct
228.5K shares-
SABS
SAB Biotherapeutics, Inc.
Jul 22, 2025
Award(A)
Warrants (right to buy)
Direct
228.5K shares-
SABS
SAB Biotherapeutics, Inc.
Jul 22, 2025
Award(A)
Warrants (right to buy)
Direct
114.3K shares-

		Type	Shares	Price		Ownership
Sep 29, 2025	SABS SAB Biotherapeutics, Inc.	Exercise(M)	1,740,000	$1.75	$3,045,000	Direct
Jul 22, 2025	SABS SAB Biotherapeutics, Inc.	Award(A) Series B Convertible Preferred Stock	228,500	-	-	Direct
Jul 22, 2025	SABS SAB Biotherapeutics, Inc.	Award(A) Warrants (right to buy)	228,500	-	-	Direct
Jul 22, 2025	SABS SAB Biotherapeutics, Inc.	Award(A) Warrants (right to buy)	114,250	-	-	Direct

1-4 of 4 transactions

About Sessa Capital (Master), L.P.

Sessa Capital (Master), L.P. (SEC CIK 0001618360) files insider reports with the SEC as Director of SAB Biotherapeutics, Inc. (SABS).

Signal8 holds 2 ownership filings by Sessa Capital (Master), L.P., all Form 4s, filed between Jul 24, 2025 and Oct 1, 2025. Those filings report 4 transactions, from Jul 22, 2025 to Sep 29, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Sessa Capital (Master), L.P.'s filings is in NEW YORK, NY.

Recent filings by Sessa Capital (Master), L.P.

Sep 29, 2025: Option exercise of SABS shares (Form 4, code M).
Jul 22, 2025: Grants or awards of SABS derivative securities (3 lines, Form 4, code A).

Other insiders filing for SAB Biotherapeutics, Inc. (SABS)

Kropotova Alexandra, CHIEF MEDICAL OFFICER
Sullivan Eddie Joe, PRESIDENT
Reich Samuel J, CEO
Bausch Christoph Lawrence, CHIEF OPERATING OFFICER
To Lucy
Jain Rita, Director

How to read Form 4 transaction codes